The absorption of carbenoxolone sodium has been studied in 15 patients with gastric ulcer and eight patients with duodenal ulcer treated for four weeks. Blood levels of carbenoxolone showed a log distribution, varied markedly between patients, and were significantly higher after Biogastrone tablets (300 mg/day) than after Duogastrone capsules (200 mg/day). Serum carbenoxolone levels were similar in patients taking Biogastrone tablets before or after meals, and in patients taking Biogastrone tablets or Duogastrone capsules with or without antacids following chronic administration. Serum carbenoxolone levels were similar in patients whose gastric ulcers had or had not healed after four weeks' treatment. Serum carbenoxolone was significantly higher in patients who developed oedema, and was significantly correlated with age and with fall in plasma potassium. Carbenoxolone may exert its metabolic effects systemically, but its ulcer-healing effects topically; additional studies are needed to test this hypothesis.
The specific gas liquid chromatographic method of Rhodes and Wright (1974) for the measurement of serum carbenoxolone has made possible investigations of the absorption of this drug. In a preliminary communication (Baron et al., 1975) we reported that blood levels varied markedly between patients and were higher in patients with gastric ulcer after Biogastrone tablets than in patients with duodenal ulcer after Duogastrone capsules. We have now extended these observations to full four week courses of treatment, and have correlated the serum carbenoxolone of the patients with their clinical, endoscopic, and metabolic responses.
Methods

PATIENTS
Fifteen patients with gastric ulcer, and eight with duodenal ulcer disease, were prescribed carbenoxolone sodium, and gave informed consent to the taking of blood samples. The diagnosis was estab-'Address for correspondence: Dr J. H. Baron lished by barium meal in every patient, by gastroscopy in each patient with gastric ulcer, and by duodenoscopy in five of the eight with duodenal ulcer disease. TREATMENT 
Gastric ulcer
The 15 patients ieceived on day 1 a single dose of carbenoxolone sodium 100 mg as Biogastrone tablets, and for the next seven days while in hospital 100 mg three times a day. This dose was continued for the next three weeks in patients 1-9, but halved to 50 mg three times a day (the manufacturers' recommended dose) in patients 10-15 (Table 1) . Patients 1-8 were allocated randomly into four pairs receiving carbenoxolone half an hour before or after food, with or without antacid (10 ml magnesium trisilicate mixture B.P.C.). One patient (ES) in error received 100 mg before meals on day 1 and after meals subsequently. Patients 9-15 received carbenoxolone after meals without antacids.
Duodenal ulcer Eight patients with duodenal ulcer received on day 1 a single dose of carbenoxolone sodium 50 mg as one Duogastrone positioned-release capsule, 30-45 minutes before breakfast. On each of the next 27 days they took one 50 mg capsule four times daily before meals. The patients were divided randomly so that four patients took the drug with, and four without antacid (see Table 2 ).
Blood sampling Venous blood samples were taken on days 1 and 2 at 0, 1, 2, 4, 6, and 8-12 hours after the first dose of drug. On days 3-8, with the patient fasting, blood was withdrawn at about 9 a.m. On days 14, 21, and 28 blood was taken in the afternoon at the clinic. Blood was taken from patients 10-15 with gastric ulcer on days 7, 14, 21, and 28 only. Plasma urea and electrolytes were determined and an aliquot of serum was stored at -20°C for subsequent analysis of carbenoxolone by the gas liquid chromatographic method of Rhodes and Wright (1974 Fig. 3 ). In the last three weeks of the study one patient receiving Duogastrone alone showed blood levels which were greater than 100 ,ug/ml. However, all the other patients, whether receiving Duogastrone alone or with antacid, showed similar blood levels ranging from 5 to 40 ,ug/ml, so AWeight(kg) (Table 3) . There were no significant correlations between mean or highest serum carbenoxolone and weight gain, or with the greatest rise in either systolic, diastolic, or mean blood pressure. There were highly significant correlations between mean or highest serum carbenoxolone and change in plasma potassium (Fig. 5) . Plasma potassium fell by more than 1 mmol/l in only one of 12 patients with mean serum carbenoxolone of less than 50 ,ug/ml, but in five out of eight patients with mean serum carbenoxolone of more than 50 ,ug/ml.
HEALING AND SIDE-EFFECTS
Twelve of the 15 patients with gastric ulcer agreed to repeat endoscopy after four weeks treatment. In nine patients the ulcers had healed completely, and, of these, four patients had oedema, and five had not. Of the three patients whose ulcers had r completely, one had oedema, and two hi the patients whose gastric ulcers healed weight gain (3-6 kg), rise in blood pressure and mean and fall in plasma potassium 0 9 mmol/l) were similar to those in pat The ulcers of two of the three patien oedema had healed, as had the ulcer c patient who had developed oedema. Pal duodenal ulcer whose ulcers had, or had r completely showed similar metabolic chai
INTER-RELATIONSHIP OF SIDE-EFFEC
The mean weight gain of 4-2 kg in seve who developed oedema was significant (p = 0-03) than the mean gain of 0-9 kg who did not develop clinical oedema. there were no significant correlations betw gain and increase in mean blood pressure in plasma potassium. It will be seen fron and 2 that parallelism between weight oedema was incomplete, so that serum c lone was related to oedema but not corre weight gain. '47/9 mm), The early studies of the absorption of carbenoxolone l (3 0 and (Downer et al., 1970; Lindup et al., 1970; ients with al., 1972) had suggested that absorption was delayed 1 and 0-8 by giving the drug in a buffer at pH 8 5 or after food. ients with The present studies confirmed our previous findings y.
that, while there was a delay in the initial absorption period in patients with gastric ulcer taking carbenoxolone as Biogastrone tablets after meals, there were no significant differences in subsequent days and weeks (Fig. 1) . Concurrent antacid did not significantly affect blood levels of carbenoxolone in patients with gastric (Fig. 2) or duodenal ulcer except p -0.6 for the initial absorption period (Fig. 3) . The serum PO* half-life of carbenoxolone calculated from the initial absorption patterns in the patients with gastric ulcers showed no effects of meals or antacids (Baron et al., 1975) . The mean half-life of 13-2 hours in seven patients with gastric ulcer with a mean age of 58 years (Baron et al., 1975) was comparable with those reported by Hayes and Langman (1975) (Fig. 4) may be due to lower dosage P = 0001). of drug, because, although the separate group of patients with gastric ulcer treated in weeks 2 to 4 with 150 mg carbenoxolone per day had blood its without levels similar to those continuing to receive 300 )f the one mg/day, those on the lower dose were also older. tients with The lower levels after Duogastrone may also reflect not, healed reduced absorption of the drug from the duodenum nges.
associated with delay in disintegration of the gelatin capsule (Galloway, 1968) and delivery of the drug TS to the duodenum rather than the stomach. Although an patients blood levels of carbenoxolone varied markedly tly greater between patients, the skew distribution could be log in patients normalised, and the mean or highest level of carHowever, benoxolone reached in the last three of the four reen weight weeks' treatment depended on the level in that or change individual patient on the seventh day. n Tables 1  gain and ULCER HEALING  : arbenoxo-There were no significant differences in the serum -lated with carbenoxolone levels between patients with gastric ulcers which healed and did not heal, but the 334 group.bmj.com on September 9, 2017 -Published by http://gut.bmj.com/ Downloaded from numbers of patients are small. The only controlled study (Doll et al., 1968) showed significantly greater healing in patients treated with 300 mg/day than with 150 mg/day, but serum levels were not measured. Unfortunately, it is not known whether carbenoxolone exerts its ulcer healing effects topically or systemically, and further dose-response studies with measurements of blood levels are needed.
SIDE-EFFECTS
Side-effects with carbenoxolone are thought to be dose-related (Turpie and Thompson, 1965; Doll et al., 1968) , and in the present study patients developing oedema had significantly higher carbenoxolone levels than those remaining free of oedema, and the fall in plasma potassium was significantly correlated with the mean or highest serum carbenoxolone (Fig. 5) . Because the two different doses of Biogastrone tablets (300 mg and 150 mg of carbenoxolone per day) achieved similar blood levels, the lower dosage is not necessarily any safer than the higher dose in producing side-effects in patients over 60 years of age.
AGE
The rise in serum carbenoxolone with age (Fig. 4) is presumably due to older patients having lower serum albumin, fewer binding sites, and decreased rates of plasma clearance of carbenoxolone (Hayes and Langman, 1975) . The correlation of serum carbenoxolone with age as well as with side-effects, provides a rational explanation for the well-known clinical impression that side-effects are common in the elderly. Serum concentrations of carbenoxolone greater than 50 jig/ml were found after seven days' treatment particularly in patients over 60, and in subsequent weeks such levels ofserum carbenoxolone were usually associated with hypokalaemia.
ULCER HEALING AND SIDE-EFFECTS
In the present study, and in that of Doll et al. (1968) , there was no correlation between ulcer healing and clinical or metabolic side-effects. If further series confirm that ulcer healing is dosedependent but independent of serum level, and sideeffects dependent on both dose and serum level but independent of ulcer-healing, then further consideration must be given to the hypothesis that the ulcerhealing effect of carbenoxolone is topical rather than systemic. 
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